DE60238393D1 - Oligonucleotidzusammenstellungen und deren verwendungen zur induktion der zelldifferenzierung - Google Patents

Oligonucleotidzusammenstellungen und deren verwendungen zur induktion der zelldifferenzierung

Info

Publication number
DE60238393D1
DE60238393D1 DE60238393T DE60238393T DE60238393D1 DE 60238393 D1 DE60238393 D1 DE 60238393D1 DE 60238393 T DE60238393 T DE 60238393T DE 60238393 T DE60238393 T DE 60238393T DE 60238393 D1 DE60238393 D1 DE 60238393D1
Authority
DE
Germany
Prior art keywords
seq
cells
compositions
differentiation
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238393T
Other languages
English (en)
Inventor
Mario C Filion
Nigel C Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DE60238393D1 publication Critical patent/DE60238393D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE60238393T 2001-04-24 2002-04-23 Oligonucleotidzusammenstellungen und deren verwendungen zur induktion der zelldifferenzierung Expired - Lifetime DE60238393D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28615801P 2001-04-24 2001-04-24
US10/127,645 US7087586B2 (en) 2001-04-24 2002-04-22 Oligonucleotide compositions and their use to induce differentiation of cells
PCT/CA2002/000573 WO2002085340A2 (en) 2001-04-24 2002-04-23 Oligonucleotide compositions and their use to induce differentiation of cells

Publications (1)

Publication Number Publication Date
DE60238393D1 true DE60238393D1 (de) 2011-01-05

Family

ID=26825829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238393T Expired - Lifetime DE60238393D1 (de) 2001-04-24 2002-04-23 Oligonucleotidzusammenstellungen und deren verwendungen zur induktion der zelldifferenzierung

Country Status (12)

Country Link
US (2) US7087586B2 (de)
EP (1) EP1381375B1 (de)
JP (1) JP4460220B2 (de)
KR (1) KR100913860B1 (de)
AT (1) ATE489467T1 (de)
AU (1) AU2002252891B2 (de)
CA (1) CA2445071A1 (de)
DE (1) DE60238393D1 (de)
IL (2) IL158534A0 (de)
MX (1) MXPA03009761A (de)
NZ (1) NZ529160A (de)
WO (1) WO2002085340A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1432450E (pt) * 2001-10-03 2006-05-31 Bioniche Life Sciences Inc Trietilenoglicol-colesteril-oligonucleotidos terapeuticamente uteis
MXPA04010415A (es) * 2002-04-22 2005-02-17 Bioniche Life Sciences Inc Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes.
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
EP1924279A2 (de) * 2005-09-07 2008-05-28 The Secretary of State for Defence Adjuvans-vakzine
EP2278979A4 (de) * 2008-05-21 2012-09-26 Us Gov Health & Human Serv Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
US8053422B2 (en) 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US5866332A (en) * 1994-02-02 1999-02-02 Incyte Pharmaceuticals, Inc. Human myeloid terminal differentiation response gene
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
CA2328406A1 (en) * 1998-05-14 1999-11-18 Hermann Wagner Methods for regulating hematopoiesis using cpg-oligonucleotides
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
MXPA02005842A (es) * 1999-12-13 2003-10-14 Bioniche Life Sciences Inc Oligonucleotidos sinteticos terapeuticamente utiles.
NZ520312A (en) 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
MXPA03001812A (es) * 2000-08-29 2004-05-21 Bioniche Life Sciences Inc Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal..
AU2002330663B2 (en) * 2001-08-17 2007-09-20 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce apoptosis

Also Published As

Publication number Publication date
JP4460220B2 (ja) 2010-05-12
US20070010472A1 (en) 2007-01-11
KR20040047749A (ko) 2004-06-05
IL158534A (en) 2010-06-16
WO2002085340A3 (en) 2003-10-30
ATE489467T1 (de) 2010-12-15
US7087586B2 (en) 2006-08-08
US20030045493A1 (en) 2003-03-06
EP1381375A2 (de) 2004-01-21
WO2002085340A2 (en) 2002-10-31
EP1381375B1 (de) 2010-11-24
NZ529160A (en) 2006-06-30
AU2002252891B2 (en) 2007-09-20
CA2445071A1 (en) 2002-10-31
MXPA03009761A (es) 2004-01-29
KR100913860B1 (ko) 2009-08-26
IL158534A0 (en) 2004-05-12
JP2004526775A (ja) 2004-09-02

Similar Documents

Publication Publication Date Title
DE69432375T2 (de) Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
ES2375058T8 (es) Axmi-010, un gen de la delta-endotoxina y métodos para su uso.
EP2186525A3 (de) G-CSF zur Behandlung der Parkinson-Krankheit
RU2013156620A (ru) Индуцирующий иммунитет агент
ATE300613T1 (de) Menschliche, für zyklische nukleotide spezifische phosphodiesterase
BR9206027A (pt) Análogo de oligonucleotídio, composto de subunidade de oligonucleotídeo, processo para preparar tal composto, processo para modular a produção ou atividade de uma proteína, e, processo para tratar um organismo tendo uma doença distinta pela produção indesejada de uma proteína
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2130839A3 (de) AXMI-027, AXMI-036 und AXMI-038, Familie von delta-Endotoxin-Genen und Verfahren zur deren Verwendung
EP2253706A3 (de) Antisense-Modulation von Kinesin-1-Expression
EP1325019A4 (de) Antisense-modulation der clusterinexpression
MX2010003606A (es) Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
WO2002102997A3 (en) Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO1999051731A3 (en) Maize histone deacetylases and their use
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE60238393D1 (de) Oligonucleotidzusammenstellungen und deren verwendungen zur induktion der zelldifferenzierung
DE69819911D1 (de) 88kda tumorgener wachstumsfaktor und antagonisten
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
DE69634074D1 (de) Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen
PL365473A1 (en) Polyamine analogues as cytotoxic agents
WO2003000656A3 (en) Antisense modulation of transforming growth factor beta receptor ii expression
IL141325A0 (en) Tan-1057 derivatives
DE60211206D1 (de) Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION